• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by SiNtx Technologies Inc.

    2/16/23 4:21:47 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care
    Get the next $SINT alert in real time by email
    SC 13G 1 ea173846-13gintra_sintx.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    SINTX Technologies, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.01 par value per share

     

    (Title of Class of Securities)

     

    829392604

    (CUSIP Number)

     

    February 7, 2023

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

      

    Page 1 of 8

     

     

    CUSIP No. 829392604

     

    1.

    Names of Reporting Persons.

     
     

    Mitchell P. Kopin

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

      (a) ☐
      (b) ☐
    3.

    SEC Use Only

       
       
    4.

    Citizenship or Place of Organization        United States of America

     
     

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5. Sole Voting Power        0
       
     
    6. Shared Voting Power        119,596
       
     
    7. Sole Dispositive Power       0
       
     
    8. Shared Dispositive Power       119,596
       
     

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person        119,596 (see Item 4)

     
     

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
       
    11.

    Percent of Class Represented by Amount in Row (9)       4.5% (see Item 4)

     
     

    12.

    Type of Reporting Person (See Instructions)

       
     

    IN; HC

      

    Page 2 of 8

     

     

    CUSIP No. 829392604

     

    1.

    Names of Reporting Persons.

     
     

    Daniel B. Asher

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

      (a) ☐
      (b) ☐
    3.

    SEC Use Only

       
       
    4.

    Citizenship or Place of Organization        United States of America

     
     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5. Sole Voting Power       0
       
     
    6. Shared Voting Power       119,596
       
     
    7. Sole Dispositive Power       0
       
     
    8. Shared Dispositive Power       119,596
       
     

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person      119,596 (see Item 4)

     
     

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
       
    11.

    Percent of Class Represented by Amount in Row (9)      4.5% (see Item 4)

     
     

    12.

    Type of Reporting Person (See Instructions)

       
     

    IN; HC

     

    Page 3 of 8

     

     

    CUSIP No. 829392604

     

    1.

    Names of Reporting Persons.

     
     

    Intracoastal Capital LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

      (a) ☐
      (b) ☐
    3.

    SEC Use Only

       
       
    4.

    Citizenship or Place of Organization        Delaware

     
     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5. Sole Voting Power       0
       
     
    6. Shared Voting Power       119,596
       
     
    7. Sole Dispositive Power       0
       
     
    8. Shared Dispositive Power       119,596
       
     

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person       119,596 (see Item 4)

     
     

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
       
    11.

    Percent of Class Represented by Amount in Row (9)       4.5% (see Item 4)

     
     

    12.

    Type of Reporting Person (See Instructions)

       
     

    OO

     

    Page 4 of 8

     

     

    Item 1.

     

    (a)Name of Issuer
       
      SINTX Technologies, Inc. (the “Issuer”)
       
     (b) Address of Issuer’s Principal Executive Offices
      
      1885 West 2100 South
      Salt Lake City, UT 84119

     

    Item 2.

     

    (a)Name of Person Filing
       
    (b)Address of Principal Business Office or, if none, Residence
       
    (c)Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

     

    The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

     

    (d)Title of Class of Securities

     

    Common Stock, $0.01 par value per share, of the Issuer (the “Common Stock”).

     

    (e)CUSIP Number

     

    829392604

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Page 5 of 8

     

     

    Item 4. Ownership.

     

    (a) and (b):

     

    (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on February 7, 2023 (the “SPA”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on February 9, 2023), each of the Reporting Persons may have been deemed to have beneficial ownership of 59,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 9.8% of the Common Stock, based on (1) 542,146 shares of Common Stock outstanding as of December 31, 2022, as reported by the Issuer, plus (2) 59,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA. The foregoing excludes (I) 59,000 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 1”) because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (II) 29,500 shares of Common Stock issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (III) 13,244 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 3”) because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (IV) 13,244 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 4”) because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (V) 733 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal (“Intracoastal Warrant 5”) because Intracoastal Warrant 5 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 174,721 shares of Common Stock.

     

    (ii) As of the close of business on February 16, 2023, each of the Reporting Persons may have been deemed to have beneficial ownership of 119,596 shares of Common Stock, which consisted of: (i) 3,875 shares of Common Stock held by Intracoastal, (ii) 59,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, (iii) 29,500 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, (iv) 13,244 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3, (v) 13,244 shares of Common Stock issuable upon exercise of Intracoastal Warrant 4 and (vi) 733 shares of Common Stock issuable upon exercise of Intracoastal Warrant 5, and all such shares of Common Stock represented beneficial ownership of approximately 4.5% of the Common Stock, based on (1) 542,146 shares of Common Stock outstanding as of December 31, 2022, as reported by the Issuer, plus (2) 1,980,000 shares of Common Stock in the aggregate issued at the closing of the transaction contemplated by the SPA, (3) 59,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, (4) 29,500 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, (5) 13,244 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3, (6) 13,244 shares of Common Stock issuable upon exercise of Intracoastal Warrant 4 and (7) 733 shares of Common Stock issuable upon exercise of Intracoastal Warrant 5.

     

    (c)Number of shares as to which each Reporting Person has:

     

    (i) Sole power to vote or to direct the vote: 0 .

     

    (ii) Shared power to vote or to direct the vote: 119,596

    .

    (iii) Sole power to dispose or to direct the disposition of 0

    .

    (iv) Shared power to dispose or to direct the disposition of 119,596

     

    Page 6 of 8

     

    .

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 7 of 8

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 16, 2023

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
         
      /s/ Daniel B. Asher
      Daniel B. Asher
         
      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

    Page 8 of 8

     

     

    Exhibit 1

     

    JOINT FILING AGREEMENT

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Date: February 16, 2023

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
         
      /s/ Daniel B. Asher
      Daniel B. Asher
         
      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

     

     

     

    Get the next $SINT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SINT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SINT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SINTX Technologies Announces Patent Issuance and Formation of Subsidiary to Advance Antimicrobial Applications in the Agribiotech Market

      SALT LAKE CITY, Utah, May 22, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced ceramics for medical device and other technical applications, announced the issuance of International Patent No. 7635292, which covers novel agricultural uses of the Company's silicon nitride (Si₃N₄) particularly in plant protection and antimicrobial treatment. This patent, combined with issued U.S. Patent No. 11,591,217, creates a family of patents focused on addressing the antimicrobial agribiotech market. SINTX remains focused on advancing silicon nitride technologies for medical applications; however, the material's broad utility allows for sel

      5/22/25 7:00:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SINTX Technologies Provides Business Update Highlighting Strategic Focus to Medical Device Commercialization

      Salt Lake City, UT , May 15, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT), an advanced ceramics company pioneering medical and antipathogenic applications of silicon nitride (Si₃N₄), today provided a comprehensive update on its operational progress, strategic initiatives, and financial position for the first quarter ended March 31, 2025. "We are executing a disciplined transformation that aligns our core capabilities in advanced ceramics with fast-growing, high-impact healthcare applications. This transition positions us for sustainable value creation," said Eric K. Olson, CEO and President of SINTX Technologies. Refocusing on High-Growth Medical Markets SINTX has ac

      5/15/25 7:05:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SINTX Technologies Announces Strategic Changes to Board of Directors

      Company positions for long-term growth in medical device markets Salt Lake City, UT, April 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT), an advanced ceramics company focused on medical device applications, today announced changes to its Board of Directors. The updates reflect the Company's ongoing strategic transformation into a focused medical technology business. Key changes include the retirement of longtime Chairman Dr. B. Sonny Bal, the appointment of President and CEO Eric Olson as Chairman of the Board, and the addition of five new directors with decades of industry expertise spanning orthopedics, spine, interventional pain, cardiovascular, medical device bu

      4/3/25 8:00:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care

    $SINT
    Financials

    Live finance-specific insights

    See more
    • SINTX Technologies Acquires Technology Assessment and Transfer, Inc.

      The Acquisition Broadens Opportunities for SINTX in Aerospace, Defense, and Biomedical Markets SALT LAKE CITY, July 06, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of advanced ceramics, announced the acquisition of Technology Assessment and Transfer, Inc. (TA&T; https://www.techassess.com/), significantly increasing SINTX's capabilities in the aerospace, defense, and biomedical markets. "We are excited to acquire TA&T and take another step towards diversifying and strengthening SINTX," said Dr. Sonny Bal, President and CEO of SINTX. "TA&T will expand our use of advanced manufacturing techno

      7/6/22 9:00:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SINTX Technologies Issues 2022 10-K and Announces Investor Conference Call

      SALT LAKE CITY, March 25, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of advanced ceramics, announced today the filing of its Annual Report on Form 10-K for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission. In 2021, SINTX made significant investments into the expansion of its three priority business segments - biomedical, industrial/armor, and antipathogenic - through the purchase of new technology, equipment, and personnel. The Company is narrowly focused on opportunities closest to revenue such as armor materials and plates, the development of new biomedi

      3/25/22 5:41:39 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SINTX Technologies Announces the Sale of First Silicon Nitride Antipathogenic Powder to O2TODAY

      SALT LAKE CITY, June 30, 2021 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of silicon nitride ceramic for medical and non-medical applications, announced today it has moved into the next phase of its relationship with O2TODAY and sold the first shipment of FleX SN-AP antipathogenic silicon nitride powder to O2TODAY for integration into a proprietary line of masks and filters. "O2TODAY announced on its website today that it is taking limited pre-orders for masks and mask filters integrated with SINTX's antipathogenic powder," said Dr. Sonny Bal, President and CEO at SINTX Technologies. "We share th

      6/30/21 9:00:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care

    $SINT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Anderson Mark Lewis bought $11,800 worth of shares (5,000 units at $2.36) (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      5/14/25 7:00:09 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • Chief Strategy Officer Honigblum Gregg R. bought $7,160 worth of shares (4,000 units at $1.79), increasing direct ownership by 40% to 14,000 units (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      5/1/25 6:10:49 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • President and CEO Olson Eric K. bought $28,088 worth of shares (14,500 units at $1.94) (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      4/30/25 2:25:41 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care

    $SINT
    SEC Filings

    See more
    • SiNtx Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Sintx Technologies, Inc. (0001269026) (Filer)

      5/22/25 7:15:34 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SiNtx Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Sintx Technologies, Inc. (0001269026) (Filer)

      5/15/25 7:10:20 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by SiNtx Technologies Inc.

      10-Q - Sintx Technologies, Inc. (0001269026) (Filer)

      5/15/25 7:00:27 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care

    $SINT
    Leadership Updates

    Live Leadership Updates

    See more
    • SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer

      Seasoned Healthcare Executive to Lead Strategic Growth Initiatives Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX's growth initiatives and enhancing investor relations. Mr. Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare secto

      11/19/24 6:00:00 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care

    $SINT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Anderson Mark Lewis bought $11,800 worth of shares (5,000 units at $2.36) (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      5/14/25 7:00:09 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • Chief Strategy Officer Honigblum Gregg R. bought $7,160 worth of shares (4,000 units at $1.79), increasing direct ownership by 40% to 14,000 units (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      5/1/25 6:10:49 AM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • President and CEO Olson Eric K. bought $28,088 worth of shares (14,500 units at $1.94) (SEC Form 4)

      4 - Sintx Technologies, Inc. (0001269026) (Issuer)

      4/30/25 2:25:41 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care

    $SINT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

      SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

      11/14/24 7:25:52 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by SiNtx Technologies Inc.

      SC 13G - Sintx Technologies, Inc. (0001269026) (Subject)

      4/1/24 4:17:43 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by SiNtx Technologies Inc. (Amendment)

      SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

      2/13/24 8:12:54 PM ET
      $SINT
      Medical/Dental Instruments
      Health Care